Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%

Reuters02-10 20:30

Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%

Harvard Bioscience Inc. reported preliminary fourth quarter (Q4) 2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evolving life sciences industry needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651631-en) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610647471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610647471","market":"nz","top_or_hot":-1,"title":"Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harvard Bioscience Inc. reported preliminary fourth quarter (Q4) 2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evolving life sciences industry needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651631-en) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harvard Bioscience Inc. reported preliminary fourth quarter (Q4) 2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evolving life sciences industry needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651631-en) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL8LXNGv:1","article_id":"2610647471","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610647471","pubTimestamp":1770726615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harvard Bioscience Inc. reported preliminary fourth quarter  2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4121":"生命科学工具和服务","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","HBIO":"哈佛生物科学","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"哈佛生物科学报告第四季度调整后EBITDA为380万美元，增长27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"HBIO":0.9},"content_text":"Harvard Bioscience reports Q4 adjusted EBITDA of USD 3.8 million, up 27%\n    \n\n        Harvard Bioscience Inc. reported preliminary fourth quarter (Q4) 2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evolving life sciences industry needs.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651631-en) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610647471","isCrawlerRequest":true}